CXCL2 combined with HVJ-E suppresses tumor growth and lung metastasis in breast cancer and enhances anti-PD-1 antibody therapy.

导出 LinkOut

翻译打印收藏纠错

作者： Yi Chun,Pan ^[1] ; Tomoyuki,Nishikawa ^[2] ; Chin Yang,Chang ^[2] ; Jiayu A,Tai ^[2] ; Yasufumi,Kaneda ^[3]

作者单位： Division of Gene Therapy Science, Graduate School of Medicine, Osaka University, Osaka 565-0871, Japan. ^[1] Department of Device Application for Molecular Therapeutics, Graduate School of Medicine, Osaka University, Osaka 565-0871, Japan. ^[2] Head Quarter, Osaka University, Osaka 565-0871, Japan. ^[3]

关键词 HVJ-E N1-type neutrophils anti-PD-1 breast cancer metastasis

DOI 10.1016/j.omto.2020.12.011

PMID 33575480

发布时间 2021-02-13

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Molecular therapy oncolytics

2021年20卷

175-186页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

CXCL2 combined with HVJ-E suppresses tumor growth and lung metastasis in breast cancer and enhances anti-PD-1 antibody therapy.

Molecular therapy oncolytics

相似文献

Molecular therapy oncolytics

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

CXCL2 combined with HVJ-E suppresses tumor growth and lung metastasis in breast cancer and enhances anti-PD-1 antibody therapy.

Molecular therapy oncolytics

相似文献

Molecular therapy oncolytics

相关期刊

检索历史清除